Condensed Consolidated Statements of Operations (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenue:
Precision oncology testing	$ 180,604	$ 133,423	$ 503,351	$ 372,060
Development services and other	10,872	9,607	33,851	36,834
Total revenue	191,476	143,030	537,202	408,894
Costs and operating expenses:
Cost of precision oncology testing	66,095	53,648	191,116	148,111
Cost of development services and other	8,394	3,966	21,090	16,424
Research and development expense	87,306	93,851	254,210	277,338
Sales and marketing expense	97,880	68,934	260,172	216,100
General and administrative expense	49,129	36,174	128,243	118,135
Total costs and operating expenses	308,804	256,573	854,831	776,108
Loss from operations	(117,328)	(113,543)	(317,629)	(367,214)
Interest income	13,257	11,690	42,038	21,477
Interest expense	(646)	(644)	(1,936)	(1,933)
Other income (expense), net	(3,007)	16,885	(47,272)	56,490
Loss before provision for income taxes	(107,724)	(85,612)	(324,799)	(291,180)
Provision for income taxes	30	490	568	1,226
Net loss	$ (107,754)	$ (86,102)	$ (325,367)	$ (292,406)
Net loss per share, basic (in usd per share)	$ (0.88)	$ (0.73)	$ (2.66)	$ (2.66)
Net loss per share, diluted (in usd per share)	$ (0.88)	$ (0.73)	$ (2.66)	$ (2.66)
Weighted-average shares used in computing net loss per share, basic (in shares)	123,051	117,736	122,406	109,791
Weighted-average shares used in computing net loss per share, diluted (in shares)	123,051	117,736	122,406	109,791